Results 271 to 280 of about 444,347 (295)

Targeting receptor complexes: a new dimension in drug discovery

Nature Reviews Drug Discovery, 2020
Mette Ishøy Rosenbaum, Louise Albertsen, David S Bredt   +2 more
exaly  

Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes

Nature Reviews Drug Discovery, 2011
Uwe Rudolph
exaly  

The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.

Journal of Medicinal Chemistry, 1990
J. Duncia, A. Chiu, D. Carini, George B. Gregory, A. Johnson, W. Price, G. Wells, P. Wong, J. Calabrese, P. Timmermans   +9 more
semanticscholar   +1 more source

Development of subtype-selective oestrogen receptor-based therapeutics

Nature Reviews Drug Discovery, 2011
Jan-Ake Gustafsson
exaly  

Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.

Journal of Medicinal Chemistry, 1991
D. Carini, J. Duncia, P. Aldrich, A. Chiu, A. Johnson, M. Pierce, W. Price, J. Santella, G. Wells, R. Wexler   +9 more
semanticscholar   +1 more source

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Cynthia Morata-Tarifa, Joyce M Slingerland   +1 more
exaly  

Targeting pathological B cell receptor signalling in lymphoid malignancies

Nature Reviews Drug Discovery, 2013
Ryan M Young, Louis M Staudt
exaly  

Angiotensin II Receptor Antagonists From Discovery to Antihypertensive Drugs

HYPERTENSION, 1991
P. Timmermans, D. Carini, A. Chiu, J. Duncia, W. Price, G. Wells, P. Wong, R. Wexler, A. Johnson   +8 more
semanticscholar   +1 more source

Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.

European Journal of Pharmacology, 2010
K. Łukawski, Agnieszka Janowska, Tomasz Jakubus, A. Tochman-Gawda, S. Czuczwar   +4 more
semanticscholar   +1 more source

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Nature Reviews Drug Discovery, 2012
P Mark Hogarth
exaly